SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-002140
Filing Date
2022-01-05
Accepted
2022-01-05 06:16:31
Documents
14
Period of Report
2021-12-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d283868d8k.htm   iXBRL 8-K 28825
2 EX-2.1 d283868dex21.htm EX-2.1 470503
3 EX-99.1 d283868dex991.htm EX-99.1 15597
  Complete submission text file 0001193125-22-002140.txt   755467

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA amrx-20211230.xsd EX-101.SCH 2885
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE amrx-20211230_lab.xml EX-101.LAB 17373
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amrx-20211230_pre.xml EX-101.PRE 10948
8 EXTRACTED XBRL INSTANCE DOCUMENT d283868d8k_htm.xml XML 3245
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 22509372
SIC: 2834 Pharmaceutical Preparations